Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
Sneha Berry, Nicolás A. Giraldo, Benjamin Green, Tricia R. Cottrell, Julie E. Stein, Elizabeth L. Engle, Haiying Xu, Aleksandra Ogurtsova, Charles A. Roberts, Daphne Wang, Peter Nguyen, Qingfeng Zhu, Sigfredo Soto-Diaz, Jose Loyola, Inbal Sander, Pok Fai Wong, Shlomit Jessel, Joshua Doyle, Danielle Signer, Richard Wilton, J. Roskes, Margaret Eminizer, Seyoun Park, Joel Sunshine, Elizabeth M. Jaffee, Alexander S. Baras, Angelo M. De Marzo, Suzanne L. Topalian, Harriet M. Kluger, Leslie Cope, Evan J. Lipson, Ludmila Danilova, Robert A. Anders, David L. Rimm, Drew M. Pardoll, Alexander S. Szalay, Janis M. Taube
Abstract
Astronomy accelerates tumor imaging Immunohistochemical stains for individual markers revolutionized diagnostic pathology decades ago but cannot capture enough information to accurately predict response to immunotherapy. Newer multiplex immunofluorescent technologies provide the potential to visualize the expression patterns of many functionally relevant molecules but present numerous challenges in accurate image analysis and data handling, particularly over large tumor areas. Drawing from the field of astronomy, in which petabytes of imaging data are routinely analyzed across a wide spectral range, Berry et al. developed a platform for multispectral imaging of whole-tumor sections with high-fidelity single-cell resolution. The resultant AstroPath platform was used to develop a multiplex immunofluorescent assay highly predictive of responses and outcomes for melanoma patients receiving immunotherapy. Science , aba2609, this issue p. eaba2609